ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

Antibiotic Resistance and MRSA

Updated on August 31, 2017

MRSA (Methicillin-resistant Staphylococcus aureus) bacteremia is associated with increased patient mortality and morbidity. As such, patient presenting with MRSA bacteremia required prompt treatment with effective antibiotics. Increasing resistance of vancomycin and emergence of vancomycin-intermediate sensitive species of MRSA (VISA/h-VISA) is encouraging infectious disease researchers to identify unique treatment regimen such as combination antibiotic treatment.

With no new antimicrobials being created and the increasing prevalence of resistance, Antimicrobial stewardship teams have employed techniques such as formulary restriction, specialised order sets implementation, treatment algorithms and guidelines designed for each institution, practitioner education, pharmacy dosing programs and pharmacodynamic dose optimization to minimized antimicrobial resistance while optimizing available therapies.[1] Furthermore, despite decreased rates of hospital-acquired (nosocomiol) MRSA infections in the UK, US and Australia due to improved infection control techniques, there’s been an increasing incidence of community-associated MRSA strains in the past fifteen years and the majority of invasive MRSA infections are currently community-acquired rather than hospital-acquired.[2]

There exists a relationship between drug concentration (pharmacokinetics) and antimicrobial effect (pharmacodynamics) and antibiotic effectiveness is either timeor concentration dependent based on the antimicrobialtypes.[1]

Vancomycin is a time-dependent antibiotic.[1] Hence, therapeutic drug concentration monitoring of peak concentrations and troughs is common practice.[1] However, AUC/MIC not T>MIC is the most predictive pharmacodynamic parameter which is opposite to the current therapeutic monitoring guidelines of 15-20mcg/mL being sufficient because a trough alone is not enough to accurately estimate a patients’s 24-hour AUC and not every patient who achieves troughs of 15-20mcg/mL are able to avhieve 24-hour AUCs which are enought to achieve an AUC/MIC >400.[1] With MIC being the denominator of this equation, any changes in MIC will dramatically affect exposure.[1] Current standard vancomycin dosing regimens aimed at achieving troughs of 15 to 20mcg/mL are sadly insufficient to obtain that target AUC/MIC of 400 when the vancomycin MIC is above 1mcg/mL therefore rendering that S.aureus with a vancomycin MIC of 2mcg/mL to be untreatable.[1]

Despite its long history and clinical studies, the optimised dosing strategy for vancomycin to optimise eradication of S.aureus while minimising nephrotoxicity is yet to be determined, hence warranting the need for other more successful treatment methods.[1]

MRSA is a serious infection and causes 20 to 50% 90-day mortality. [2] Daptomycin is the only other approved drug treatment for MRSA bacteremia but it has not shown to be superior to vancomycin. [2]Other alternative agents for MRSA-B treatment include linezolid, daptomycin and ceftaroline but although these are non-inferior to vancomycin in treating MRSA infections, none proved superior and all have significant adverse effects risks and are costly.[2] Moreover, none showed synergistic bactericidal activity when combined with vancomycin against MRSA.[2]

Some examples that demonstrate relevance of this gained knowledge of the nefits of combination antimicrobial therapy against MRSA:

There is consistent in-vitro and in-vivo laboratory results proving the synergy between vancomycin or daptomycin and an anti-staphylococcal β-lactam antibiotic as well as increasing clinical data to support these combinations to improve outcomes from this common and serious infection such as a recent pilot randomised controlled trial CAMERA-2 which reported a reduction in bacteremia duration from using vancomycin and flucloxacillin combined versus vancomycin monotherapy. [2] The benefits of adding anti-staphylococcal β-lactams to standard MRSA therapy are safety, wide availability and low cost.[2] Furthermore, vancomycin showed slower bactericidal activity poorer tissue penetration and slower bacteremia clearance compared to anti-staphylococcal β-lactams (oxacillin and its derivatives flucloxacillin, cloxacillin and nafcillin).[2]

In a single-centre retrospective cohort study (50 patients with MRSA-B), Dilworth and colleagues reported a higher rate of microbiological eradication in the combination therapy group (vancomycin and at least 24 hours of β-lactam) versus vancomycin monotherapy (96% versus 80%, P=0.02). [2] CAMERA-1 (prospective clinical trial, open-label design) by Davis et al. included the randomisation of 60 patients to vancomycin or combined therapy (vancomycin and flucloxacillin) conducted in seven Australian centres reported mean bacteremia clearance of 2 versus 3 days with standard therapy (P=0.06). [2]

A case-series of seven patients with persistent MRSA-B for longer than a week despite high-dose daptomycin reported 100% bacteremia clearance within 48 hours of adding naficillin or oxacillin to their treatment.[2] A second case series of 22 patients with persistent MRSA-B despite daptomycin for a median of ten days revealed 100% bacteremia clearance in a median of 2 days after ceftaroline as added.[2]

Thus the synergistic antimicrobial effect is related to the ability of β-lactams of enhancing daptomycin’s ability to bind to the bacterial cell wall. [2] Due to the deletion of the MecA gene in some strains of VISA and vancomycin-resistant Staphylococcus aureus, increasing vancomycin-resistance is surprisingly associated with decreasing MICs to oxacillin and thi s synergism effect could be attributed to structural changes on penicillin-binding proteins and cell-wall thickness.[2] Sakoulas et al. also reported novel data from an ex-vivo study of human blood which further substantiates the potential advantage of β-lactams for MRSA through causing increased activity of the innate host defence peptides like cathelicidin LL-37 thus resulting in a more efficient bactericidal activity.[2]

Reflection& relevance to pharmacy practice

I have learnt through numerous studies thathave linked higher minimum inhibitory concentrations (MICs) of antimicrobials against any specific pathogen with clinical failure and mortality, thus requiring new strategies of optimizing antibiotic therapy to enhance treatment success and maintain safety of medicines.[1] Some ways in which we can optimize the quality use of medicines in clinical practice and prevent antibiotic resistance is to consider dosage optimization guided by pharmacodynamics and pharmacokinetics, considering antimicrobial concentration and duration of therapy to its potency and effectiveness as well as the successful synergistic combination of different groups of antimicrobials to improve therapeutic outcomes, successful eradication of pathogen, prevent or minimise adverse effects associated with medicine use and medicine costs and availability.[1,2]

Through employing these methods, we are then able to optimize pharmaceutical therapy according to best evidence-based data in clinical practice.

REFERENCES

1) Connors KP, Kuti JL and NicolauDP.Optimizing antibiotic pharmacodynamics for clinical practice.Pharmaceut Anal Acta.2013;4(3):1-8

2) Tong SY, Nelson J, Paterson DL, Fowler VG, Howden BP, Cheng AC et al. CAMERA2-combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials. [Internet].2016 Mar ;17:170. Available from: https://www-ncbi-nlm-nih-gov.ezproxy.utas.edu.au/pmc/articles/PMC4815121/

Comments

    0 of 8192 characters used
    Post Comment

    No comments yet.

    working

    This website uses cookies

    As a user in the EEA, your approval is needed on a few things. To provide a better website experience, hubpages.com uses cookies (and other similar technologies) and may collect, process, and share personal data. Please choose which areas of our service you consent to our doing so.

    For more information on managing or withdrawing consents and how we handle data, visit our Privacy Policy at: https://hubpages.com/privacy-policy#gdpr

    Show Details
    Necessary
    HubPages Device IDThis is used to identify particular browsers or devices when the access the service, and is used for security reasons.
    LoginThis is necessary to sign in to the HubPages Service.
    Google RecaptchaThis is used to prevent bots and spam. (Privacy Policy)
    AkismetThis is used to detect comment spam. (Privacy Policy)
    HubPages Google AnalyticsThis is used to provide data on traffic to our website, all personally identifyable data is anonymized. (Privacy Policy)
    HubPages Traffic PixelThis is used to collect data on traffic to articles and other pages on our site. Unless you are signed in to a HubPages account, all personally identifiable information is anonymized.
    Amazon Web ServicesThis is a cloud services platform that we used to host our service. (Privacy Policy)
    CloudflareThis is a cloud CDN service that we use to efficiently deliver files required for our service to operate such as javascript, cascading style sheets, images, and videos. (Privacy Policy)
    Google Hosted LibrariesJavascript software libraries such as jQuery are loaded at endpoints on the googleapis.com or gstatic.com domains, for performance and efficiency reasons. (Privacy Policy)
    Features
    Google Custom SearchThis is feature allows you to search the site. (Privacy Policy)
    Google MapsSome articles have Google Maps embedded in them. (Privacy Policy)
    Google ChartsThis is used to display charts and graphs on articles and the author center. (Privacy Policy)
    Google AdSense Host APIThis service allows you to sign up for or associate a Google AdSense account with HubPages, so that you can earn money from ads on your articles. No data is shared unless you engage with this feature. (Privacy Policy)
    Google YouTubeSome articles have YouTube videos embedded in them. (Privacy Policy)
    VimeoSome articles have Vimeo videos embedded in them. (Privacy Policy)
    PaypalThis is used for a registered author who enrolls in the HubPages Earnings program and requests to be paid via PayPal. No data is shared with Paypal unless you engage with this feature. (Privacy Policy)
    Facebook LoginYou can use this to streamline signing up for, or signing in to your Hubpages account. No data is shared with Facebook unless you engage with this feature. (Privacy Policy)
    MavenThis supports the Maven widget and search functionality. (Privacy Policy)
    Marketing
    Google AdSenseThis is an ad network. (Privacy Policy)
    Google DoubleClickGoogle provides ad serving technology and runs an ad network. (Privacy Policy)
    Index ExchangeThis is an ad network. (Privacy Policy)
    SovrnThis is an ad network. (Privacy Policy)
    Facebook AdsThis is an ad network. (Privacy Policy)
    Amazon Unified Ad MarketplaceThis is an ad network. (Privacy Policy)
    AppNexusThis is an ad network. (Privacy Policy)
    OpenxThis is an ad network. (Privacy Policy)
    Rubicon ProjectThis is an ad network. (Privacy Policy)
    TripleLiftThis is an ad network. (Privacy Policy)
    Say MediaWe partner with Say Media to deliver ad campaigns on our sites. (Privacy Policy)
    Remarketing PixelsWe may use remarketing pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to advertise the HubPages Service to people that have visited our sites.
    Conversion Tracking PixelsWe may use conversion tracking pixels from advertising networks such as Google AdWords, Bing Ads, and Facebook in order to identify when an advertisement has successfully resulted in the desired action, such as signing up for the HubPages Service or publishing an article on the HubPages Service.
    Statistics
    Author Google AnalyticsThis is used to provide traffic data and reports to the authors of articles on the HubPages Service. (Privacy Policy)
    ComscoreComScore is a media measurement and analytics company providing marketing data and analytics to enterprises, media and advertising agencies, and publishers. Non-consent will result in ComScore only processing obfuscated personal data. (Privacy Policy)
    Amazon Tracking PixelSome articles display amazon products as part of the Amazon Affiliate program, this pixel provides traffic statistics for those products (Privacy Policy)